Comparison of baseline characteristics and grade 3/4 treatment-related side effects in patients randomized to daily and weekly schedules of 2-CdA administration 2-CdA indicates 2-chlorodeoxyadenosine
| Parameter . | 2-CdA daily, n = 62 . | 2-CdA weekly, n = 54 . | P . |
|---|---|---|---|
| Patient characteristics | |||
| Median age, y (range) | 53 (27-78) | 57 (25-86) | .33 |
| Male, no. (%) | 41 (66) | 37 (68) | .74 |
| Median time from diagnosis, mo (range) | 0.4 (0-37.8) | 0.1 (0-13.4) | .21 |
| Median white cell count, × G/L (range) | 2.2 (0.7-30.0) | 2.8 (0.7-34.0) | .09 |
| Median absolute neutrophil count, × G/L (range) | 0.42 (0.0-4.5) | 0.66 (0.1-2.0) | .48 |
| Median hemoglobin level, g/L (range) | 9.9 (3.7-15.2) | 10.8 (4.3-16.4) | .42 |
| Median platelet count, × G/L (range) | 66 (1-301) | 86 (2-238) | .02 |
| Lymphadenopathy, no. (%) | 8 (13) | 8 (15) | .76 |
| Splenomegaly, no. (%) | 38 (63) | 31 (57) | .68 |
| Hepatomegaly, no. (%) | 5 (8) | 12 (22) | .03 |
| Treatment side effects | |||
| Progression of neutropenia, no. (%) | 29 (47) | 25 (47) | .97 |
| Neutropenia below 0.5 G/L, no. (%) | 36 (58) | 28 (52) | .27 |
| Neutropenia below 1.0 G/L, no. (%) | 38 (61) | 28 (52) | .20 |
| Progression of thrombocytopenia, no. (%) | 10 (16) | 9 (17) | .93 |
| Platelet transfusions, U | 47 | 39 | .21 |
| Progression of anemia, no. (%) | 9 (15) | 10 (19) | .58 |
| Red cell transfusions, U | 47 | 40 | .82 |
| All infections, including fever of unknown origin, no. (%) | 11 (18) | 14 (26) | .28 |
| Pneumonia, no. (%) | 5 (8) | 4 (7) | .87 |
| Urinary tract infections, no. (%) | 1 (2) | 2 (4) | .49 |
| Other infections, no. (%) | 3 (5) | 5 (9) | .37 |
| Fever of unknown origin, no. (%) | 2 (3) | 5 (9) | .18 |
| Time to infection, d (range) | 6 (1-14) | 11 (3-28) | .09 |
| Duration of infection, d (range) | 5 (1-60) | 13 (3-28) | .27 |
| Septic deaths, no. (%) | 2 (3) | 1 (2) | .64 |
| Allergic symptoms, no. (%) | 1 (2) | 2 (4) | .49 |
| Second malignancies, no. (%) | 4 (6) | 3 (6) | .50 |
| Parameter . | 2-CdA daily, n = 62 . | 2-CdA weekly, n = 54 . | P . |
|---|---|---|---|
| Patient characteristics | |||
| Median age, y (range) | 53 (27-78) | 57 (25-86) | .33 |
| Male, no. (%) | 41 (66) | 37 (68) | .74 |
| Median time from diagnosis, mo (range) | 0.4 (0-37.8) | 0.1 (0-13.4) | .21 |
| Median white cell count, × G/L (range) | 2.2 (0.7-30.0) | 2.8 (0.7-34.0) | .09 |
| Median absolute neutrophil count, × G/L (range) | 0.42 (0.0-4.5) | 0.66 (0.1-2.0) | .48 |
| Median hemoglobin level, g/L (range) | 9.9 (3.7-15.2) | 10.8 (4.3-16.4) | .42 |
| Median platelet count, × G/L (range) | 66 (1-301) | 86 (2-238) | .02 |
| Lymphadenopathy, no. (%) | 8 (13) | 8 (15) | .76 |
| Splenomegaly, no. (%) | 38 (63) | 31 (57) | .68 |
| Hepatomegaly, no. (%) | 5 (8) | 12 (22) | .03 |
| Treatment side effects | |||
| Progression of neutropenia, no. (%) | 29 (47) | 25 (47) | .97 |
| Neutropenia below 0.5 G/L, no. (%) | 36 (58) | 28 (52) | .27 |
| Neutropenia below 1.0 G/L, no. (%) | 38 (61) | 28 (52) | .20 |
| Progression of thrombocytopenia, no. (%) | 10 (16) | 9 (17) | .93 |
| Platelet transfusions, U | 47 | 39 | .21 |
| Progression of anemia, no. (%) | 9 (15) | 10 (19) | .58 |
| Red cell transfusions, U | 47 | 40 | .82 |
| All infections, including fever of unknown origin, no. (%) | 11 (18) | 14 (26) | .28 |
| Pneumonia, no. (%) | 5 (8) | 4 (7) | .87 |
| Urinary tract infections, no. (%) | 1 (2) | 2 (4) | .49 |
| Other infections, no. (%) | 3 (5) | 5 (9) | .37 |
| Fever of unknown origin, no. (%) | 2 (3) | 5 (9) | .18 |
| Time to infection, d (range) | 6 (1-14) | 11 (3-28) | .09 |
| Duration of infection, d (range) | 5 (1-60) | 13 (3-28) | .27 |
| Septic deaths, no. (%) | 2 (3) | 1 (2) | .64 |
| Allergic symptoms, no. (%) | 1 (2) | 2 (4) | .49 |
| Second malignancies, no. (%) | 4 (6) | 3 (6) | .50 |